Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 3 |
2022 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Front Immunol. 2021 Jul 5;12:682492. doi: 10.3389/fimmu.2021.682492. eCollection 2021.
Front Immunol. 2021.
PMID: 34290704
Free PMC article.
Review.
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.
Ellingsen EB, Bjørheim J, Gaudernack G.
Ellingsen EB, et al.
Curr Opin Oncol. 2023 Mar 1;35(2):100-106. doi: 10.1097/CCO.0000000000000922. Epub 2023 Jan 16.
Curr Opin Oncol. 2023.
PMID: 36700456
Free PMC article.
Review.
Item in Clipboard
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor-specific HLA variants.
Anzar I, Sverchkova A, Samarakoon P, Ellingsen EB, Gaudernack G, Stratford R, Clancy T.
Anzar I, et al. Among authors: ellingsen eb.
HLA. 2022 Apr;99(4):313-327. doi: 10.1111/tan.14562. Epub 2022 Feb 10.
HLA. 2022.
PMID: 35073457
Free PMC article.
Item in Clipboard
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G.
Ellingsen EB, et al.
J Transl Med. 2022 Sep 11;20(1):419. doi: 10.1186/s12967-022-03624-z.
J Transl Med. 2022.
PMID: 36089578
Free PMC article.
Clinical Trial.
Item in Clipboard
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM.
Ellingsen EB, et al.
J Immunother Cancer. 2022 May;10(5):e004345. doi: 10.1136/jitc-2021-004345.
J Immunother Cancer. 2022.
PMID: 35613827
Free PMC article.
Item in Clipboard
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.
Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å.
Haakensen VD, et al. Among authors: ellingsen eb.
J Transl Med. 2021 May 31;19(1):232. doi: 10.1186/s12967-021-02905-3.
J Transl Med. 2021.
PMID: 34059094
Free PMC article.
Clinical Trial.
Item in Clipboard
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G.
Aamdal E, et al. Among authors: ellingsen eb.
Front Immunol. 2021 May 11;12:663865. doi: 10.3389/fimmu.2021.663865. eCollection 2021.
Front Immunol. 2021.
PMID: 34046035
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite